FDA Seeks Feedback on Risks from Autonomous/Remote Teleoperation Medical Devices
The U.S. Food and Drug Administration (FDA) is seeking feedback on the benefits and risks of implementing autonomous and remotely operated medical devices in healthcare and has published a paper – Evaluating Benefit-Risk in Robotic Medical Devices with Autonomous or Remote Teleoperation Capabilities – to start a discussion. The FDA states that the paper does not constitute draft or final guidance, and is intended to inform future FDA policy development responsive to innovation, while maintaining device safety and effectiveness.
Currently, the FDA has yet to issue U.S. marketing authorization for either fully autonomous or teleoperated robotic devices but states that it is committed to ensuring that patients continue to have access to safe, secure, and effective medical devices. The FDA has already authorized robotically assisted surgical devices for use in the United States, and innovations in artificial intelligence and machine learning, along with advances in connectivity, mean autonomous and remote teleoperation capabilities could potentially be utilized to deliver care to patients more effectively. The FDA is looking to open up a conversation about these emerging capabilities to help inform future policy decisions and is seeking feedback on what it describes as “increasingly complex considerations” concerning device safety and effectiveness.
The FDA is seeking feedback specifically on autonomy rather than automaticity. The latter concerns following strict, programmed, and completely predictable rules, whereas autonomy involves making decisions in response to changing external conditions, which increases risk. The discussion is intended to cover all degrees of autonomy, such as performing discrete tasks while a human is in charge up to full autonomy, and remotely teleoperated devices, which can be controlled by a clinician who is not present in the operating room or other care setting.
While the FDA seeks information on robotic surgical systems, the paper covers a wide range of devices and systems capable of performing diagnostic, therapeutic, or rehabilitative tasks on human anatomy, such as positioning and/or controlling instruments and imaging tools, and open, minimally invasive, non-invasive, or endoluminal surgical or interventional procedures. The FDA is seeking feedback from stakeholders with experiences and perspectives on the benefits and risks of using increasingly autonomous robotic device systems, to help ensure that they can be regulated to ensure their safety and effectiveness throughout the total product life cycle.
The benefits are numerous and include more consistent and repeatable results, reducing the risk of adverse events through human imprecision or lack of experience, more effective planning, and easing the strain on clinicians. There are naturally risks associated with autonomous devices, as AI-powered systems have shown that they are also capable of error, may perform poorly in situations outside of their training data, or may drift over time. In the case of autonomous surgical devices, there are risks associated with unexpected or irregular anatomy, their ability to control bleeding, and must allow clinicians to rapidly take control if the necessity arises. Risk also has the potential to increase with the level of autonomy.
Remote teleoperation has tremendous benefits, one of the most important being to expand the treatments available to patients in underserved areas. Highly skilled surgeons could remotely perform procedures in hospitals in underserved areas, rather than requiring patients to travel long distances for treatment, allowing time-critical procedures to be provided rapidly. Connectivity issues are a significant risk, as is the ability to manage complications remotely. The FDA specifically requests feedback on how quickly procedures can switch from remote operation to manual, whether local expertise is required, and how fast a patient can be escalated or transferred.
Cybersecurity is a key concern. Connected devices, including autonomous and remotely operated medical devices, are cyber devices under Section 524B of the FD&C Act. As such, the FDA’s cybersecurity requirements for premarket submissions will apply. While not specifically mentioned in the discussion paper, these include an SBOM, patch management, and postmarket vulnerability monitoring and disclosure. Autonomy increases the threat surface, and a cybersecurity threat could compromise a system’s functionality, availability, and data integrity. Further, as users take a more supervisory role, they may not have sufficient bandwidth to address cybersecurity vulnerabilities.
Autonomy and remote teleoperation introduce risks independently, but those risks may be compounded when both capabilities are present in the same system. There are also sensor or imaging data integrity risks, where systems are reliant on data to see and act. The FDA has identified cybersecurity considerations in previous guidance and warns that devices/systems can be rendered nonfunctional due to cybersecurity incidents or design vulnerabilities, and availability must be maintained at both the control and procedural ends.
The FDA is looking at an end-to-end system perspective rather than the examination of isolated individual components to identify system-level threats. Authentication, integrity, and non-repudiation controls would need to be robust; otherwise, the accuracy of commands could not be guaranteed and confirmed as having been issued by authorized individuals. Another key consideration is threats that users at either end may not be able to see, such as if a video feed has been tampered with, which may not be apparent at a patient’s bedside, for example.
The FDA has asked 15 questions to guide discussion. “The questions posed throughout this paper are intended to solicit the perspectives, expertise, and practical experience of the broader stakeholder community,” explained the FDA. “FDA is seeking to develop a regulatory approach that would rigorously and appropriately mitigate risks while championing the meaningful benefits these technologies offer.” The FDA seeks feedback by January 5, 2027.
In addition to the discussion paper, the FDA is also hosting a hybrid two-day public workshop on December 2-3 to advance the understanding of autonomous and remote teleoperated robotic medical devices. Registration is required by November 23, 2026.
